论文部分内容阅读
[目的]通过检测表皮生长因子受体EGFR在肾细胞癌中的表达,探讨它们与肾癌的发生、病理亚型、临床分期的关系。[方法]按2004年WHO肾细胞肿瘤分类标准对114例肾细胞癌分型,免疫组织化学方法检测114例肾癌石蜡标本中EGFR蛋白的表达,分析肿瘤的TNM分期并随访患者,进行统计学分析。[结果]EGFR在全组阳性率为51.8%(56/114)。在肾透明细胞癌中阳性率为54.5%(42/77),乳头状肾癌中阳性率为45.4%(5/11),肾嫌色细胞癌中表达50.0%(7/14),Xp11.2易位性肾癌中阳性率为60%(6/10),肾未分化癌中无表达(0/2),EGFR在各亚型、TNM各期间阳性率均无统计学差异。[结论]EGFR可能参与肾癌的发生发展,是否可对其选用EGFR受体抑制剂化疗值得探讨。
[Objective] To investigate the relationship between the expression of epidermal growth factor receptor (EGFR) in renal cell carcinoma (RCC) and the occurrence of renal cell carcinoma (RCC), pathological subtypes and clinical stage. [Method] 114 cases of renal cell carcinoma were classified according to the WHO classification of renal cell tumor in 2004, and the expression of EGFR protein in 114 cases of renal cell carcinoma was detected by immunohistochemistry. The TNM stage of the tumor was analyzed and the patients were followed up for statistical analysis analysis. [Results] The positive rate of EGFR in the whole group was 51.8% (56/114). The positive rate was 54.5% (42/77) in renal clear cell carcinoma, 45.4% (5/11) in papillary renal carcinoma and 50.0% (7/14) in renal cell carcinoma, Xp11. 2 translocation of renal cell carcinoma was 60% (6/10), no expression in renal undifferentiated carcinoma (0/2), EGFR in each subtypes, TNM the positive rate was not statistically different. [Conclusion] EGFR may be involved in the occurrence and development of renal cell carcinoma, and whether its use of EGFR receptor inhibitor chemotherapy is worth exploring.